Should diphenhydramine be used in a patient with chronic kidney disease (CKD) stage 4?

Diphenhydramine Should Be Avoided in CKD Stage 4

Diphenhydramine should not be routinely used in patients with CKD stage 4 due to lack of safety data, high protein binding that prevents dialysis clearance, risk of accumulation and toxicity, and availability of safer alternatives.

Rationale Based on Guidelines and Evidence

The 2024 KDIGO guidelines emphasize that people with CKD are more susceptible to nephrotoxic effects of medications and specifically recommend reviewing and limiting over-the-counter medicines that may be harmful 1. Diphenhydramine falls squarely into this category as an OTC medication with concerning properties in advanced CKD.

Key Pharmacokinetic Concerns

Diphenhydramine is highly protein-bound to albumin, which creates a critical problem in CKD stage 4:

• Limited dialyzability: The high protein binding prevents effective removal even with dialysis, predisposing patients to side effects and accumulation 2
• Lack of dosing guidance: There is a notable absence of safety profile data and specific dosing information for the ESKD population 2
• Potential for nephrotoxicity: Case reports document diphenhydramine-associated acute kidney injury 3

Clinical Practice Considerations

The KDIGO guidelines mandate considering GFR when dosing renally-cleared medications 1. However, for diphenhydramine specifically:

• No established dose adjustments exist for CKD stage 4 (GFR 15-29 mL/min/1.73m²)
• The FDA labeling provides no guidance on renal dosing 4
• Clinicians are urged to "use caution" in this population due to unknown dosing and toxicity thresholds 2

Anticholinergic Burden

The FDA warnings highlight multiple concerns that are amplified in CKD stage 4 4:

• Urinary retention (especially problematic with potential prostate issues)
• CNS effects including marked drowsiness and paradoxical excitability
• Drug interactions with sedatives

These anticholinergic effects can accumulate dangerously when clearance is impaired.

Practical Approach

When antihistamine therapy is needed in CKD stage 4:

• Consider second-generation antihistamines (cetirizine, fexofenadine) which have better-defined renal dosing
• For pruritus in CKD, address the underlying uremia rather than masking with antihistamines
• For sleep disturbances, explore non-pharmacologic interventions first

If diphenhydramine must be used:

• Use the lowest effective dose
• Extend dosing intervals beyond the standard 4-6 hours
• Monitor closely for CNS effects, urinary retention, and anticholinergic toxicity
• Document clear indication and plan for discontinuation 1

Common Pitfalls to Avoid

1. Assuming OTC = safe: The guideline specifically warns against this assumption in CKD 1
2. Using standard dosing: The pharmacokinetic alterations in CKD stage 4 make standard dosing inappropriate 5, 6
3. Ignoring drug accumulation: Without renal clearance data, assume accumulation will occur
4. Failing to consider alternatives: Safer options almost always exist for the intended indication

The evidence consistently points toward avoidance rather than dose adjustment, given the lack of safety data and concerning pharmacokinetic profile in advanced CKD 2, 7.